Labcorp.

Company Snapshot

Founded: 1995
Entity Type: Public
Employees: 70,000
Region: North America
Revenue: $13,008.9 Millions
Revenue Year: 2024
Segment: Diagnostics Laboratories (Dx)
Headquarter: Delaware, U.S.
Key Geographics: North America, Europe and Others
Corporate Address: 358 South Main Street, Burlington, North Carolina, Delaware 27215 U.S. Tel. +1-336-229-1127 www.labcorp.com

Company Overview

LabCorp is a globally recognized life sciences company dedicated to delivering critical insights that empower physicians, hospitals, pharmaceutical firms, researchers, and patients to make informed and confident decisions.

Operating through its Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD) divisions, the company offers diagnostic services, drug development support, and technology-driven solutions. These services collectively facilitate over 160 million patient interactions annually, equating to more than 3 million weekly engagements.

By integrating Invitae’s genetic testing technology, LabCorp will now offer a complete set of colorectal cancer testing for each patient – from testing to diagnosis to treatment.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
Operating Income: ***

This information is available for BCC Research members only.

Labcorp. In Reports

Global DNA Forensics Market

BCC Research Market Analyst says global market for DNA forensics is projected to grow from an estimated $3.3 billion in 2025 to $4.7 billion by the end of 2030, at a CAGR of 7.7%.

Global Colorectal Cancer Screening and Diagnostics Market

BCC Research Report: Dive into Colorectal Cancer Screening and Diagnostics Market estimates, data is provided for 2021 and 2022 as historical years, 2023 as the base year, and forecasts extend through 2029.

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

BCC Research Market Analyst says global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029

Company's Business Segments

  • Diagnostics Laboratories (Dx) : Diagnostics Laboratories (Dx), which includes routine testing and specialty/esoteric testing
  • Biopharma Laboratory Services (BLS) : Biopharma Laboratory Services (BLS), consisting of Early Development Research Laboratories and Central Laboratory Services

Applications/End User Industries

  • Physicians
  • Hospitals
  • Health Systems
  • Accountable Care Organizations
  • Medicare
  • Managed Care Organizations
  • Endocrinology
  • Life-Changing Therapeutics
  • Oncology
  • Rheumatology
  • Weight Loss Management
  • Health Wellness
  • Advancing Preventive Care
  • Neurology
  • Neuroimmunology
  • Cardiometabolic
  • Immunodeficiency
  • Transplant
  • Hepatitis
AI Sentiment